Bonnie C. Carney

Dr. Bonnie C. Carney


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2022 in European Burn Journal
Verified
Journal Article
Open access
PDF file
EKedward kelly
edward kelly
MOMary Oliver
Mary Oliver
BCBonnie C. Carney
Bonnie C. Carney
JSJeffrey W. Shupp
Jeffrey W. Shupp
Burn injury is debilitating and among one of the most frequently occurring traumas. Critical care improvements have allowed for increasingly positive outcomes. However, infection, whether it be localized to the site of the wound or systemic in nature, remains a serious cause of morbidity and mortality. Immune suppression predisposes the burn population to the development of invasive infections; and this along with the possibility of inhalation injury puts them at a significant risk for mortality. Emerging multi-drug-resistant pathogens, including Staphylococcus aureus, Enterococcus, Pseudomonas, Acinetobacter, Enterobacter, and yeast spp., continue to complicate clinical care measures, requiring innovative therapies and antimicrobial treatment. Close monitoring of antimicrobial regimens, strict decontamination procedures, early burn eschar removal, adequate wound closure, proper nutritional maintenance, and management of shock and resuscitation all play a significant role in mitigating infection. Novel antimicrobial therapies such as ultraviolet light, cold plasma and topical antiseptics must continue to evolve in order to lower the burden of infection in burn.

10 January 2024 in Burns
Verified
Journal Article
Closed access
MOMary A. Oliver
Mary A. Oliver
LHLou’ay K. Hussein
Lou’ay K. Hussein
EMEsteban A. Molina
Esteban A. Molina
JKJohn W. Keyloun
John W. Keyloun
SMSydney M. McKnight
Sydney M. McKnight
BCBonnie C. Carney
Bonnie C. Carney

19 October 2020 in Wound Repair and Regeneration
Verified
Journal Article
Closed access
PDF file
LKLiam D. Kirkpatrick
Liam D. Kirkpatrick
JSJeffrey W. Shupp
Jeffrey W. Shupp
RSRobert D. Smith
Robert D. Smith
AAAbdulnaser Alkhalil
Abdulnaser Alkhalil
LMLauren T. Moffatt
Lauren T. Moffatt
BCBonnie C. Carney
Bonnie C. Carney

25 March 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BCBonnie C. Carney
Bonnie C. Carney
TTTaryn E. Travis
Taryn E. Travis
LMLauren T. Moffatt
Lauren T. Moffatt
LJLaura S. Johnson
Laura S. Johnson
MMMelissa M. McLawhorn
Melissa M. McLawhorn
JSJeffrey W. Shupp
Jeffrey W. Shupp
There are limited treatments for dyschromia in burn hypertrophic scars (HTSs). Initial work in Duroc pig models showed that regions of scar that are light or dark have equal numbers of melanocytes. This study aims to confirm melanocyte presence in regions of hypo- and hyper-pigmentation in an animal model and patient samples. In a Duroc pig model, melanocyte presence was confirmed usingen facestaining. Patients with dyschromic HTSs had demographic, injury details, and melanin indices collected. Punch biopsies were taken of regions of hyper-, hypo-, or normally pigmented scar and skin. Biopsies were processed to obtain epidermal sheets (ESs). A subset of ESs wereen facestained with melanocyte marker, S100β. Melanocytes were isolated from a different subset. Melanocytes were treated with NDP α-MSH, a pigmentation stimulator. mRNA was isolated from cells, and was used to evaluate gene expression of melanin-synthetic genes. In patient and pig scars, regions of hyper-, hypo-, and normal pigmentation had significantly different melanin indices. S100βen facestaining showed that regions of hyper- and hypo-pigmentation contained the same number of melanocytes, but these cells had different dendricity/activity. Treatment of hypo-pigmented melanocytes with NDP α-MSH produced melanin by microscopy. Melanin-synthetic genes were upregulated in treated cells over controls. While traditionally it may be thought that hypopigmented regions of burn HTS display this phenotype because of the absence of pigment-producing cells, these data show that inactive melanocytes are present in these scar regions. By treating with a pigment stimulator, cells can be induced to re-pigment.

5 April 2019 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
AAAbdulnaser Alkhalil
Abdulnaser Alkhalil
BCBonnie C. Carney
Bonnie C. Carney
TTTaryn E. Travis
Taryn E. Travis
SMSeid Muhie
Seid Muhie
SMStacy Ann Miller
Stacy Ann Miller
JSJeffrey W. Shupp
Jeffrey W. Shupp

Verified
Journal Article
Open access
PDF file
Dean S RosenthalDean S Rosenthal
Dean S Rosenthal
YHYogameenakshi Haribabu
Yogameenakshi Haribabu
SVsahar vakili
sahar vakili
LKLi-Wei Kuo
Li-Wei Kuo
HCHelen Havens Clark
Helen Havens Clark
Dean S RosenthalDean S Rosenthal
Dean S Rosenthal
Malignant melanoma is a lethal skin cancer containing melanoma-initiating cells (MIC) implicated in tumorigenesis, invasion, and drug resistance, and is characterized by the elevated expression of stem cell markers, including CD133. The siRNA knockdown of CD133 enhances apoptosis induced by the MEK inhibitor trametinib in melanoma cells. This study investigates the underlying mechanisms of CD133’s anti-apoptotic activity in patient-derived BAKP and POT cells, harboring difficult-to-treat NRASQ61K and NRASQ61R drivers, after CRISPR-Cas9 CD133 knockout or Dox-inducible expression of CD133. MACS-sorted CD133(+) BAKP cells were conditionally reprogrammed to derive BAKR cells with sustained CD133 expression and MIC features. Compared to BAKP, CD133(+) BAKR exhibit increased cell survival and reduced apoptosis in response to trametinib or the chemotherapeutic dacarbazine (DTIC). CRISPR-Cas9-mediated CD133 knockout in BAKR cells (BAKR-KO) re-sensitized cells to trametinib. CD133 knockout in BAKP and POT cells increased trametinib-induced apoptosis by reducing anti-apoptotic BCL-xL, p-AKT, and p-BAD and increasing pro-apoptotic BAX. Conversely, Dox-induced CD133 expression diminished apoptosis in both trametinib-treated cell lines, coincident with elevated p-AKT, p-BAD, BCL-2, and BCL-xL and decreased activation of BAX and caspases-3 and -9. AKT1/2 siRNA knockdown or inhibition of BCL-2 family members with navitoclax (ABT-263) in BAKP-KO cells further enhanced caspase-mediated apoptotic PARP cleavage. CD133 may therefore activate a survival pathway where (1) increased AKT phosphorylation and activation induces (2) BAD phosphorylation and inactivation, (3) decreases BAX activation, and (4) reduces caspases-3 and -9 activity and caspase-mediated PARP cleavage, leading to apoptosis suppression and drug resistance in melanoma. Targeting nodes of the CD133, AKT, or BCL-2 survival pathways with trametinib highlights the potential for combination therapies for NRAS-mutant melanoma stem cells for the development of more effective treatments for patients with high-risk melanoma.